ACE Inhibitor News and Research

RSS
ACE inhibitors act to reduce hypertension by interfering with the conversion of angiotensin I to artery-constricting angiotensin II. Blocking the production of angiotensin II results in arterial vasodilation and an accompanying reduction in blood pressure. ACE inhibitors currently are recommended as first-line therapy for hypertension in certain patient populations, because of their safety and efficacy.
Study shows heart medications prevent cardiovascular damage during breast cancer treatment

Study shows heart medications prevent cardiovascular damage during breast cancer treatment

Lisinopril oral solution approved for treatment of hypertension in children and adults

Lisinopril oral solution approved for treatment of hypertension in children and adults

Aliskiren fails to show benefit for heart failure patients with diabetes

Aliskiren fails to show benefit for heart failure patients with diabetes

Tackling insulin resistance may reduce recurrence after stroke

Tackling insulin resistance may reduce recurrence after stroke

Common hypertension drugs worsen cardiovascular outcomes in hypertensive African Americans

Common hypertension drugs worsen cardiovascular outcomes in hypertensive African Americans

UT Southwestern evaluates allopurinol drug to prevent nephropathy in Type I diabetes patients

UT Southwestern evaluates allopurinol drug to prevent nephropathy in Type I diabetes patients

Researchers elucidate mechanism that induces skeletal muscle atrophy in patients with congestive heart failure

Researchers elucidate mechanism that induces skeletal muscle atrophy in patients with congestive heart failure

FDA approves new heart failure drug

FDA approves new heart failure drug

Novartis announces FDA approval of Entresto to reduce risk of cardiovascular death, heart failure hospitalization

Novartis announces FDA approval of Entresto to reduce risk of cardiovascular death, heart failure hospitalization

Regulus Therapeutics reports net loss of $22.2 million for fourth quarter 2014

Regulus Therapeutics reports net loss of $22.2 million for fourth quarter 2014

Novartis’ heart failure medicine LCZ696 granted FDA priority review

Novartis’ heart failure medicine LCZ696 granted FDA priority review

Novartis receives priority review status from FDA for heart failure medicine LCZ696

Novartis receives priority review status from FDA for heart failure medicine LCZ696

Early use of heart failure drugs slows cardiac damage in boys, young men with DMD

Early use of heart failure drugs slows cardiac damage in boys, young men with DMD

Australian Prescriber publishes top 10 subsidised drugs in Australia

Australian Prescriber publishes top 10 subsidised drugs in Australia

New preclinical study shows RG-012 may provide therapeutic benefit for Alport syndrome patients

New preclinical study shows RG-012 may provide therapeutic benefit for Alport syndrome patients

FDA approves Epaned for treatment of symptomatic and asymptomatic heart failure

FDA approves Epaned for treatment of symptomatic and asymptomatic heart failure

Transparency Life receives SBIR program grant to fund Phase 2a proof-of-concept study for MS

Transparency Life receives SBIR program grant to fund Phase 2a proof-of-concept study for MS

Investigational LCZ696 drug: A real breakthrough for patients with heart failure

Investigational LCZ696 drug: A real breakthrough for patients with heart failure

FDA accepts Symplmed's Prestalia NDA for hypertension treatment

FDA accepts Symplmed's Prestalia NDA for hypertension treatment

PARADIGM-HF trial of LCZ696 for chronic heart failure stopped early for benefit

PARADIGM-HF trial of LCZ696 for chronic heart failure stopped early for benefit